GLMD

Galmed Pharmaceu

• PR Newswire·03/31 20:15

  Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

• Reuters·03/18 11:46

  Galmed Pharmaceuticals Ltd. CSO Liat Nissimov Brueck filed Form 3 initial beneficial ownership statement

• Reuters·03/18 11:46

  Galmed Pharmaceuticals Ltd. CFO Doron Leib Cohen files initial beneficial ownership statement

• Reuters·03/18 11:46

  Galmed Pharmaceuticals names Chief Accounting Officer Yohai Stenzler in initial beneficial ownership filing

• Reuters·03/18 11:46

  Galmed Pharmaceuticals names CEO Allen Baharaff in initial beneficial ownership filing

• TipRanks·03/05 21:27

  Galmed Pharmaceuticals Shareholders Approve Proposal at Special Meeting

• TipRanks·03/04 22:08

  Galmed Pharmaceuticals Adjourns Special Shareholder Meeting for Lack of Quorum

• Reuters·03/04 21:18

  Galmed Pharmaceuticals Delays Shareholder Meeting to March 5

• TipRanks·02/09 21:50

  Galmed Pharmaceuticals Sets March 4 Vote on Reverse Stock Split to Address Nasdaq Listing Deficiency

• Benzinga·02/05 21:05

  12 Health Care Stocks Moving In Thursday's After-Market Session

• TipRanks·01/30 21:58

  Galmed Pharmaceuticals Receives Nasdaq Minimum Bid Price Deficiency Notice

• Seeking Alpha·01/30 21:29

  Galmed Pharmaceuticals receives Nasdaq bid price deficiency notice

• Benzinga·01/30 21:15

  Galmed Pharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through July 28 To Regain Compliance

• Reuters·01/30 21:15

  Galmed Pharmaceuticals Faces Nasdaq Delisting Risk Over Minimum Bid Price

• Reuters·01/30 21:15

  GALMED PHARMACEUTICALS ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID PRICE NOTIFICATION